Open-house contract for Aclidiniumbromid/Formoterol
Titre original de l'avis
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2024-06 - Aclidiniumbromid/Formoterol (Wirkstoffkombination)
Score d'opportunité
Pourquoi ce score ?
Opportunité
45 / 100
Complexité
58 / 100
Facteurs de risque
The notice says offers/contracts cannot be submitted through the portal and must be sent by email with qualified electr...
Only pharmaceutical undertakings meeting the AMG-based eligibility conditions and exclusion declarations may participat...
Submission deadline in 3 days
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Aug 2026
- Conclude rebate contracts under § 130c SGB V for the product combination Aclidiniumbromid/Formoterol.
- Provide supplies of the relevant pharmaceutical products under an open-house model.
Afficher le résumé complet
Open-house supply arrangement in Germany for the pharmaceutical product combination Aclidiniumbromid/Formoterol, led by Techniker Krankenkasse. The notice states that contracts may be concluded with all suitable pharmaceutical companies under uniform conditions, without individual negotiations or exclusivity. Electronic submission via the portal is not allowed; contracts must be submitted by email with qualified electronic signature or by post, and the participation documents are only available to companies that market or credibly intend to market the relevant product. No contract value is stated.
Risques
The notice says offers/contracts cannot be submitted through the portal and must be sent by email with qualified electr...
Only pharmaceutical undertakings meeting the AMG-based eligibility conditions and exclusion declarations may participat...
Submission deadline in 3 days
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Applicant must be a pharmaceutical undertaking in the sense of § 4(18) AMG for the offered medicinal products.
- Applicant must have its seat in the AMG territory, another EU Member State, or another EEA State.
- Applicant must have a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.
Critères d'attribution
Lot 1
Acheteur
Localisation
Hamburg, DEU
Site web
Identifiant
992-80116-93
Activité
Health
Lots (1)
LOT-0001
Open-house contract for Aclidiniumbromid/Formoterol
Supply lot for the medicinal product combination Aclidiniumbromid/Formoterol under an open-house rebate contract. The contract is open to all eligible pharmaceutical companies, with no exclusivity and no individual negotiation. Lot information comes from structured data and the notice text.
Localisation
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
Open-house procedure with uniform conditions
the stated award criteria field has no substantive criterion value and is described in the notice as having no further meaning.
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Open House Originale Rabattverträge 2024-06 - Aclidiniumbromid/Formoterol (Wirkstoffkombination)
Description TED originale
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c SGB V zur Wirkstoffkombination Aclidiniumbromid/Formoterol zu schließen.
Détails de la procédure
- Date de publication
- 15 Jul 2024
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 422415-2024
Documents (1)
Appels d'offres similaires
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Score d'opportunité
Pourquoi ce score ?
Opportunité
45 / 100
Complexité
58 / 100
Facteurs de risque
The notice says offers/contracts cannot be submitted through the portal and must be sent by email with qualified electr...
Only pharmaceutical undertakings meeting the AMG-based eligibility conditions and exclusion declarations may participat...
Submission deadline in 3 days
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications